Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Planned maintenance
A system upgrade is planned for 17/11-2026, at 12:00-13:00. During this time DiVA will be unavailable.
Change search
Link to record
Permanent link

Direct link
Li, Yanying
Publications (3 of 3) Show all publications
Kahlous, N. A., Rinne, M. K., Zhang, X., Li, Y., Chen, Y., Motso, A., . . . Carlsson, J. (2026). Molecular mechanisms of native ligand selectivity in catecholamine G protein-coupled receptors. Nature Communications, 17(1), Article ID 4112.
Open this publication in new window or tab >>Molecular mechanisms of native ligand selectivity in catecholamine G protein-coupled receptors
Show others...
2026 (English)In: Nature Communications, E-ISSN 2041-1723, Vol. 17, no 1, article id 4112Article in journal (Refereed) Published
Abstract [en]

Activation of G protein-coupled receptors (GPCRs) by extracellular ligands is crucial for cellular communication and modulates numerous physiological processes. Despite sharing highly similar orthosteric binding sites, catecholamine GPCRs exhibit exquisite selectivity for their native agonists, even among nearly identical chemical messengers. However, the molecular basis and evolution of receptor selectivity remain poorly understood. To elucidate the structural mechanisms of GPCR selectivity, we focus on the prototypical human β2-adrenergic and D1 dopaminergic receptors, which are important drug targets and respond to the catecholamines adrenaline/noradrenaline and dopamine, respectively. Guided by structural and sequence data, we identify a small set of residues responsible for ligand selectivity. By exchanging residues at four positions in the β-adrenergic receptors and seven in the D1-like dopaminergic receptors, we swap the pharmacological profiles of the two subfamilies. Unexpectedly, the switch in selectivity not only involves residues interacting with the ligand, but is also controlled by regions outside the orthosteric binding site. Cryo-electron microscopy structures and computational models of the mutant receptors identify distinct molecular mechanisms contributing to selectivity in a concerted manner. Our findings provide insights into GPCR evolution and highlight strategies for protein engineering and drug design.

Place, publisher, year, edition, pages
Springer Nature, 2026
National Category
Bioinformatics and Computational Biology Structural Biology
Identifiers
urn:nbn:se:uu:diva-582961 (URN)10.1038/s41467-026-71361-8 (DOI)001758509800001 ()42026038 (PubMedID)2-s2.0-105038432398 (Scopus ID)
Note

De tre första författarna delar förstaförfattarskapet

Available from: 2026-03-23 Created: 2026-03-23 Last updated: 2026-08-27Bibliographically approved
Li, Y., He, X., Wang, P., Yuan, B., Pan, Y., Hu, X., . . . Li, J. (2024). A D-Y Shaped Neuropeptide Y Mimetic Peptide-Dye Self-Assembly with Maximal Emission Beyond 1300 nm and Glioma Mitochondrial Activity Modulation. Small, 20(13), Article ID 2308621.
Open this publication in new window or tab >>A D-Y Shaped Neuropeptide Y Mimetic Peptide-Dye Self-Assembly with Maximal Emission Beyond 1300 nm and Glioma Mitochondrial Activity Modulation
Show others...
2024 (English)In: Small, ISSN 1613-6810, E-ISSN 1613-6829, Vol. 20, no 13, article id 2308621Article in journal (Refereed) Published
Abstract [en]

Neuropeptide Y (NPY), as one of the most abundant neuropeptides known, is widely distributed in the central and peripheral nervous system. However, most of the reported NPY-mimetic peptides are hard to cross the blood-brain barrier, target glioma mitochondria, and achieve self-assembly nanostructure in situ. Here, based on the α-helix structure of the novel chiral NPY-mimetic peptides D/LNPY(14), a Y-shaped peptide is designed with the sequences that can be recognized by enterokinase and achieved nanofibers conversion in glioma cell mitochondria. Coupling the Y-shaped NPY-mimetic peptide with the NIR-II fluorophore IR1048, a red-shifting of the fluorescence spectrum beyond 1300 nm is achieved through self-assembly. After the self-assembly in glioma mitochondria, the formed nanofibers can promote intracellular mitochondrial ROS production and extend the NIR-II fluorescence imaging time to at least 7 days in vivo. This work for the first time endows the self-assembly of α-helical-based chiral NPY-mimetic peptides, providing a novel strategy for glioma subcellular regulation enhanced antitumor treatment guided by NIR-II fluorescence imaging.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
Keywords
D-peptide ligand, neuropeptide Y, NIR-II imaging, self-assembly, Y-1 receptor
National Category
Biochemistry Molecular Biology
Identifiers
urn:nbn:se:uu:diva-529848 (URN)10.1002/smll.202308621 (DOI)001126750800001 ()38109130 (PubMedID)
Available from: 2024-06-05 Created: 2024-06-05 Last updated: 2025-02-20Bibliographically approved
Wang, M.-D., Yi, L., Li, Y., Xu, R., Hu, J., Hou, D.-Y., . . . Wang, H. (2024). Homologous Peptide Foldamer Promotes FUS Aggregation and Triggers Cancer Cell Death. Journal of the American Chemical Society, 146(42), 28669-28676
Open this publication in new window or tab >>Homologous Peptide Foldamer Promotes FUS Aggregation and Triggers Cancer Cell Death
Show others...
2024 (English)In: Journal of the American Chemical Society, ISSN 0002-7863, E-ISSN 1520-5126, Vol. 146, no 42, p. 28669-28676Article in journal (Refereed) Published
Abstract [en]

Fused in sarcoma (FUS), a multifunctional deoxyribonucleic acid (DNA)/ribonucleic acid (RNA)-binding protein, has been implicated in various cancer types, including sarcoma and leukemia. Despite its association with these diseases, there has been limited exploration of FUS as a cancer therapy target, primarily because its dynamic nature makes it difficult to target specifically. In this study, we explored a kind of beta-sheet peptide foldamer, named beta(4)-TAT, to influence FUS aggregation by targeting its RNA recognition motifs (RRM). This approach leverages the noncovalent interaction characteristics of peptide self-assembly processes. The beta(4) sequence, derived from the FUS RRM beta-sheet, in combination with TAT, a peptide known for its nuclear targeting capability, enables beta(4)-TAT to bind specifically to the analogous beta(4) sequence within FUS. Notably, beta(4)-TAT effectively induces FUS aggregation within cells, leading to the death of cancer cells. Our work developed a novel peptide foldamer-based strategy for inducing protein aggregation, paving the way for innovative therapeutic approaches in targeting FUS-associated cancers.

Place, publisher, year, edition, pages
American Chemical Society (ACS), 2024
National Category
Neurosciences Cell and Molecular Biology
Identifiers
urn:nbn:se:uu:diva-548972 (URN)10.1021/jacs.4c03420 (DOI)001333398600001 ()39403745 (PubMedID)
Available from: 2025-02-10 Created: 2025-02-10 Last updated: 2025-02-10Bibliographically approved
Organisations

Search in DiVA

Show all publications